142 related articles for article (PubMed ID: 30085668)
1. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.
Hudson L; Mui J; Vázquez S; Carvalho DM; Williams E; Jones C; Bullock AN; Hoelder S
J Med Chem; 2018 Aug; 61(16):7261-7272. PubMed ID: 30085668
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ALK2 with bicyclic pyridyllactams.
Witten MR; Wu L; Lai CT; Kapilashrami K; Pusey M; Gallagher K; Chen Y; Yao W
Bioorg Med Chem Lett; 2022 Jan; 55():128452. PubMed ID: 34780900
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
4. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel ALK2 inhibitors and their effect on cancer cells.
Kim M; Choi O; Pyo S; Choi SU; Park CH
Biochem Biophys Res Commun; 2017 Oct; 492(1):121-127. PubMed ID: 28782519
[TBL] [Abstract][Full Text] [Related]
6. Bis-Heteroaryl Pyrazoles: Identification of Orally Bioavailable Inhibitors of Activin Receptor-Like Kinase-2 (R206H).
Sekimata K; Sato T; Sakai N; Watanabe H; Mishima-Tsumagari C; Taguri T; Matsumoto T; Fujii Y; Handa N; Honma T; Tanaka A; Shirouzu M; Yokoyama S; Miyazono K; Hashizume Y; Koyama H
Chem Pharm Bull (Tokyo); 2019; 67(3):224-235. PubMed ID: 30828000
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
8. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
[TBL] [Abstract][Full Text] [Related]
9. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
10. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for specificity of TGFβ family receptor small molecule inhibitors.
Ogunjimi AA; Zeqiraj E; Ceccarelli DF; Sicheri F; Wrana JL; David L
Cell Signal; 2012 Feb; 24(2):476-483. PubMed ID: 21983015
[TBL] [Abstract][Full Text] [Related]
12. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Smil D; Wong JF; Williams EP; Adamson RJ; Howarth A; McLeod DA; Mamai A; Kim S; Wilson BJ; Kiyota T; Aman A; Owen J; Poda G; Horiuchi KY; Kuznetsova E; Ma H; Hamblin JN; Cramp S; Roberts OG; Edwards AM; Uehling D; Al-Awar R; Bullock AN; O'Meara JA; Isaac MB
J Med Chem; 2020 Sep; 63(17):10061-10085. PubMed ID: 32787083
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
[TBL] [Abstract][Full Text] [Related]
14. Identification of small molecule inhibitors of ALK2: a virtual screening, density functional theory, and molecular dynamics simulations study.
Kausar T; Nayeem SM
J Mol Model; 2018 Aug; 24(9):262. PubMed ID: 30159679
[TBL] [Abstract][Full Text] [Related]
15. Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.
Ensan D; Smil D; Zepeda-Velázquez CA; Panagopoulos D; Wong JF; Williams EP; Adamson R; Bullock AN; Kiyota T; Aman A; Roberts OG; Edwards AM; O'Meara JA; Isaac MB; Al-Awar R
J Med Chem; 2020 May; 63(9):4978-4996. PubMed ID: 32369358
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and
Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
[TBL] [Abstract][Full Text] [Related]
18. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.
Hamasaki M; Hashizume Y; Yamada Y; Katayama T; Hohjoh H; Fusaki N; Nakashima Y; Furuya H; Haga N; Takami Y; Era T
Stem Cells; 2012 Nov; 30(11):2437-49. PubMed ID: 22949078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
